<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04478591</url>
  </required_header>
  <id_info>
    <org_study_id>2020.191</org_study_id>
    <nct_id>NCT04478591</nct_id>
  </id_info>
  <brief_title>The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis</brief_title>
  <acronym>WOC</acronym>
  <official_title>The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this research is to study the prevalence of the wearing-off effect and&#xD;
      possible risk factors for wearing-off symptoms in patients with multiple sclerosis using&#xD;
      ocrelizumab with the use of questionnaires. Furthermore, the goal is to study whether&#xD;
      patients receiving extended dosing of ocrelizumab experience more wearing-off symptoms or&#xD;
      adverse events in general. Finally, we would like to extend knowledge on wearing-off symptoms&#xD;
      in general.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ocrelizumab is a monoclonal antibody very effective for the treatment of relapsing-remitting&#xD;
      multiple sclerosis and primary progressive multiple sclerosis. Ocrelizumab is usually&#xD;
      administered intravenous every six months. Natalizumab is another type of treatment used for&#xD;
      relapsing-remitting multiple sclerosis and is administered every four weeks. Often patients&#xD;
      report MS-related symptoms just prior to their next infusion such as fatigue, coordination&#xD;
      problems or motor problems, the so-called wearing-off phenomenon. The exact etiology of this&#xD;
      phenomenon remains unknown. Although not studied before, patients do report similar symptoms&#xD;
      when using ocrelizumab. Furthermore, because of the COVID-19 pandemic, some patients receive&#xD;
      extended dosing of ocrelizumab based on b-cell count. Whether this can increase wearing-off&#xD;
      symptoms is unknown.&#xD;
&#xD;
      The goal of this research is to study the prevalence of wearing-off symptoms and possible&#xD;
      risk factors for wearing-off symptoms in patients with multiple sclerosis using ocrelizumab.&#xD;
      All patients using ocrelizumab during one year or more that provided written informed consent&#xD;
      to participate in the study will be asked to complete three questionnaires before or during&#xD;
      their next treatment with ocrelizumab. The questionnaires that will be used are the MSIS-29,&#xD;
      the treatment satisfaction questionnaire and a questionnaire about wearing-off symptoms.&#xD;
      Exact weight of the participants will be measured. Information about age, gender, date of&#xD;
      diagnosis, start date of ocrelizumab, clinical and radiological disease activity, EDSS score,&#xD;
      b-cell count and the biomarker neurofilament light will be extracted from the patient files.&#xD;
      After two weeks, participants receive two additional digital questionnaires, the MSIS-29 and&#xD;
      a follow-up questionnaire about wearing-off symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wearing-off symptoms</measure>
    <time_frame>Baseline</time_frame>
    <description>Prevalence of wearing-off symptoms prior to ocrelizumab infusion (yes/no assessed on questionnaires)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of wearing-off symptoms (yes/no assessed on questionnaires) in correlation to the % of patients with extended dosing versus standard dosing with ocrelizumab.</measure>
    <time_frame>At baseline (prior to next infusion with ocrelizumab)</time_frame>
    <description>% of wearing-off symptoms (yes/no assessed on questionnaires) in correlation to the % of patients with extended dosing versus standard dosing with ocrelizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament light levels in patients with wearing-off symptoms.</measure>
    <time_frame>At baseline (prior to next infusion with ocrelizumab)</time_frame>
    <description>Neurofilament light levels in patients with wearing-off symptoms compared to patients without wearing-off symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute B-cells count in blood in correlation to the presence of wearing-off symptoms (yes/no assessed on questionnaires)</measure>
    <time_frame>At baseline (prior to next infusion with ocrelizumab)</time_frame>
    <description>Absolute B-cells count in blood in correlation to the presence of wearing-off symptoms (yes/no assessed on questionnaires) levels in patients with wearing-off symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of multiple sclerosis (either RRMS or PPMS) in correlation to % of patients with wearing-off symptoms (yes/no assessed on questionnaires).</measure>
    <time_frame>At baseline (prior to next infusion with ocrelizumab)</time_frame>
    <description>Type of multiple sclerosis (either RRMS or PPMS) in correlation to % of patients with wearing-off symptoms (yes/no assessed on questionnaires).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction score measured by the treatment satisfaction questionnaire in correlation to the % of patients with wearing-off symptoms (yes/no assessed on questionnaires)</measure>
    <time_frame>At baseline (prior to next infusion with ocrelizumab)</time_frame>
    <description>Treatment satisfaction score measured by the treatment satisfaction questionnaire in correlation to the % of patients with wearing-off symptoms (yes/no assessed on questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported disability (MSIS-29 questionnaire) compared before and after ocrelizumab infusion in patients with wearing-off symptoms</measure>
    <time_frame>At baseline (prior to next infusion with ocrelizumab) and after two weeks</time_frame>
    <description>Self-reported disability before ocrelizumab infusion compared before and after ocrelizumab (delta scores) in patients with wearing-off symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported disability (MSIS-29 questionnaire) after ocrelizumab infusion in patients without wearing-off symptoms</measure>
    <time_frame>At baseline (prior to next infusion with ocrelizumab) and after two weeks</time_frame>
    <description>Self-reported disability after ocrelizumab infusioSelf-reported disability before ocrelizumab infusion compared before and after ocrelizumab (delta scores) in patients with wearing-off symptomsn in patients without wearing-off symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of wearing-off symptoms after ocrelizumab infusion in patients with wearing-off symptoms</measure>
    <time_frame>Two weeks after ocrelizumab infusion</time_frame>
    <description>Change of wearing-off symptoms after ocrelizumab infusion in patients with wearing-off symptoms as measured with the wearing-off questionnaire (questionnaire designed for this study evaluating wearing-off symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose symptoms after ocrelizumab infusion</measure>
    <time_frame>Two weeks after ocrelizumab infusion</time_frame>
    <description>Post-dose symptoms after ocrelizumab infusion as measured with the wearing-off questionnaire (questionnaire designed for this study evaluating wearing-off symptoms).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">117</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patients with multiple sclerosis using ocrelizumab.</arm_group_label>
    <description>Patients with multiple sclerosis using ocrelizumab for a minimum of one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).</description>
    <arm_group_label>Patients with multiple sclerosis using ocrelizumab.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with multiple sclerosis using ocrelizumab.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Diagnosis multiple sclerosis&#xD;
&#xD;
          -  Use of ocrelizumab as a treatment for multiple sclerosis for a minimum of one year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to answer questionnaires in Dutch&#xD;
&#xD;
          -  Different infusion protocol during the previous ocrelizumab infusion (e.g. 300 mg of&#xD;
             ocrelizumab instead of 600 mg).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joep Killestein, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam UMC, location VUmc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <state>North-Holland</state>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Zo√© van Kempen</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Ocrelizumab</keyword>
  <keyword>Wearing-off effect</keyword>
  <keyword>Neurofilament Light</keyword>
  <keyword>Extended dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

